BODY MASS INDEX, NOT DYSLIPIDEMIA, IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN AMYOTROPHIC LATERAL SCLEROSIS

被引：236

作者：

Paganoni, Sabrina ^{[2
]}

Deng, Jing ^{[1
]}

Jaffa, Matthew ^{[1
]}

Cudkowicz, Merit E. ^{[1
]}

Wills, Anne-Marie ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurol Clin Trials Unit, Charlestown, MA 02129 USA

[2] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Boston, MA USA

来源：

MUSCLE & NERVE | 2011年 / 44卷 / 01期

关键词：

ALS; BMI; cholesterol; HDL; LDL; lipid; obesity; survival; DENSITY LIPOPROTEIN-CHOLESTEROL; NUTRITIONAL-STATUS; ALS PATIENTS; TRIAL; DIAGNOSIS; WEIGHT;

D O I：

10.1002/mus.22114

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Introduction: Recent studies have provided conflicting data regarding the role of dyslipidemia in amyotrophic lateral sclerosis (ALS). The aim of this study was to determine whether cholesterol level are an independent predictor of survival in ALS. Methods: Cholesterol levels were measured in 427 ALS subjects from three clinical trial databases. Results: The LDL/HDL ratio did not decrease over time, despite significant declines in body mass index (BMI), forced vital capacity (FVC), and ALSFRS-R. After adjusting for BMI, FVC, and age, the lipid ratio was not associated with survival. There was a 'U'-shaped association between BMI and mortality, with the highest survival at 30-35 kg/m(2). The adjusted hazard ratio for the linear association between BMI and survival was 0.860 (95% CI 0.80-0.93, P = 0.0001). Conclusions: We found that dyslipidemia is not an independent predictor of survival in ALS. BMI is an independent prognostic factor for survival after adjusting for markers of disease severity. Muscle Nerve 44: 20-24, 2011

引用

页码：20 / 24

页数：5

共 22 条

[1] Hypermetabolism in ALS patients: an early and persistent phenomenon
Bouteloup, C.
Desport, J. -C.
Clavelou, P.
Guy, N.
Derumeaux-Burel, H.
Ferrier, A.
Couratier, P.
[J]. JOURNAL OF NEUROLOGY, 2009, 256 (08) : 1236 - 1242
[2] El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, BR
Miller, RG
Swash, M
Munsat, TL
[J]. AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS, 2000, 1 (05): : 293 - 299
[3] DIFFERENTIAL CHANGES IN PLASMA HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL LEVELS IN OBESE MEN AND WOMEN DURING WEIGHT-REDUCTION
BROWNELL, KD
STUNKARD, AJ
[J]. ARCHIVES OF INTERNAL MEDICINE, 1981, 141 (09) : 1142 - 1146
[4] Lower serum lipid levels are related to respiratory impairment in patients with ALS
Chio, A.
Calvo, A.
Ilardi, A.
Cavallo, E.
Moglia, C.
Mutani, R.
Palmo, A.
Galletti, R.
Marinou, K.
Papetti, L.
Mora, G.
[J]. NEUROLOGY, 2009, 73 (20) : 1681 - 1685
[5] A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis
Cudkowicz, ME
Shefner, JM
Schoenfeld, DA
Brown, RH
Johnson, H
Qureshi, M
Jacobs, M
Rothstein, JD
Appel, SH
Pascuzzi, RM
Heiman-Patterson, TD
Donofrio, PD
David, WS
Russell, JA
Tandan, R
Pioro, EP
Felice, KJ
Rosenfeld, J
Mandler, RN
Sachs, GM
Bradley, WG
Raynor, EM
Baquis, GD
Belsh, JM
Novella, S
Goldstein, J
Hulihan, J
[J]. NEUROLOGY, 2003, 61 (04) : 456 - 464
[6] Trial of celecoxib in amyotrophic lateral sclerosis
Cudkowicz, Merit E.
Shefner, Jeremy M.
Schoenfeld, David A.
Zhang, Hui
Andreasson, Katrin I.
Rothstein, Jeffrey D.
Drachman, Daniel B.
[J]. ANNALS OF NEUROLOGY, 2006, 60 (01) : 22 - 31
[7] Desport JC, 2000, AMYOTROPH LATERAL SC, V1, P91
[8] Nutritional status is a prognostic factor for survival in ALS patients
Desport, JC
Preux, PM
Truong, TC
Vallat, JM
Sautereau, D
Couratier, P
[J]. NEUROLOGY, 1999, 53 (05) : 1059 - 1063
[9] Desport JC, 2001, AM J CLIN NUTR, V74, P328
[10] Hypermetabolism in ALS: Correlations with Clinical and Paraclinical Parameters
Desport, Jean-Claude
Torny, Frederic
Lacoste, Mathieu
Preux, Pierre-Marie
Couratier, Philippe
[J]. NEURODEGENERATIVE DISEASES, 2005, 2 (3-4) : 202 - 207

← 1 2 3 →